NO996205L - Behandling av insulinresistens med veksthormonutskillelsesmiddel - Google Patents

Behandling av insulinresistens med veksthormonutskillelsesmiddel

Info

Publication number
NO996205L
NO996205L NO996205A NO996205A NO996205L NO 996205 L NO996205 L NO 996205L NO 996205 A NO996205 A NO 996205A NO 996205 A NO996205 A NO 996205A NO 996205 L NO996205 L NO 996205L
Authority
NO
Norway
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretion
secretion
Prior art date
Application number
NO996205A
Other languages
English (en)
Norwegian (no)
Other versions
NO996205D0 (no
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Treadway
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO996205D0 publication Critical patent/NO996205D0/no
Publication of NO996205L publication Critical patent/NO996205L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO996205A 1997-06-25 1999-12-15 Behandling av insulinresistens med veksthormonutskillelsesmiddel NO996205L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO996205D0 NO996205D0 (no) 1999-12-15
NO996205L true NO996205L (no) 1999-12-15

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996205A NO996205L (no) 1997-06-25 1999-12-15 Behandling av insulinresistens med veksthormonutskillelsesmiddel

Country Status (40)

Country Link
US (3) US6448263B1 (OSRAM)
EP (1) EP1000085B1 (OSRAM)
JP (2) JP2000514099A (OSRAM)
KR (1) KR20010014224A (OSRAM)
CN (2) CN1152049C (OSRAM)
AP (1) AP1145A (OSRAM)
AR (1) AR012256A1 (OSRAM)
AT (1) ATE305477T1 (OSRAM)
AU (1) AU747510B2 (OSRAM)
BG (1) BG104008A (OSRAM)
BR (1) BR9810477A (OSRAM)
CA (1) CA2294464A1 (OSRAM)
CO (1) CO4950621A1 (OSRAM)
DE (1) DE69831745T2 (OSRAM)
DZ (1) DZ2539A1 (OSRAM)
EA (1) EA002089B1 (OSRAM)
EG (1) EG21712A (OSRAM)
ES (1) ES2248899T3 (OSRAM)
HN (1) HN1998000088A (OSRAM)
HR (1) HRP980361A2 (OSRAM)
HU (1) HUP0001922A3 (OSRAM)
ID (1) ID24345A (OSRAM)
IL (7) IL154111A0 (OSRAM)
IN (1) IN189724B (OSRAM)
IS (1) IS5275A (OSRAM)
MA (1) MA24581A1 (OSRAM)
NO (1) NO996205L (OSRAM)
NZ (1) NZ500655A (OSRAM)
OA (1) OA11242A (OSRAM)
PA (1) PA8452601A1 (OSRAM)
PE (1) PE105399A1 (OSRAM)
PL (1) PL337659A1 (OSRAM)
SK (1) SK175699A3 (OSRAM)
TN (1) TNSN98113A1 (OSRAM)
TR (1) TR199903257T2 (OSRAM)
TW (1) TW553943B (OSRAM)
UA (1) UA64751C2 (OSRAM)
WO (1) WO1998058949A1 (OSRAM)
YU (1) YU70199A (OSRAM)
ZA (1) ZA985546B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
MX2007007396A (es) * 2004-12-21 2007-08-14 Hercules Inc Resinas cationicas reactivas para usarse como agentes de resistencia secos y humedos en sistemas de fabricacion de papel que contienen iones sulfito.
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
MX2009008574A (es) 2007-02-09 2009-12-09 Tranzyme Pharma Inc Moduladores del receptor de grelina macrociclicos y metodos para usar el mismo.
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
HK1217700A1 (zh) 2013-05-28 2017-01-20 Raqualia Pharma Inc. 多晶型物形式
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US9873695B2 (en) * 2014-08-05 2018-01-23 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
KR20170078612A (ko) * 2014-10-31 2017-07-07 라퀄리아 파마 인코포레이티드 그렐린 수용체 효능제로서 테트라히드로피라졸로피리딘 유도체
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
EP0669830A4 (en) 1992-11-06 1997-02-26 Merck & Co Inc SUBSTITUTED DIPEPTIDE ANALOGS PROMOTING THE RELEASE OF GROWTH HORMONE.
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
DE69637855D1 (de) 1995-12-22 2009-04-16 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
WO1998058947A1 (en) * 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
US6630487B2 (en) 2003-10-07
DE69831745T2 (de) 2006-08-31
NZ500655A (en) 2002-02-01
IS5275A (is) 1999-11-26
IL154114A0 (en) 2003-07-31
AR012256A1 (es) 2000-09-27
MA24581A1 (fr) 1998-12-31
IL154111A0 (en) 2003-07-31
IL154115A0 (en) 2003-07-31
EA002089B1 (ru) 2001-12-24
EP1000085B1 (en) 2005-09-28
CN1152049C (zh) 2004-06-02
NO996205D0 (no) 1999-12-15
TW553943B (en) 2003-09-21
IN189724B (OSRAM) 2003-04-19
PA8452601A1 (es) 2000-05-24
AP9801267A0 (en) 1998-06-30
WO1998058949A1 (en) 1998-12-30
EP1000085A1 (en) 2000-05-17
AU7445698A (en) 1999-01-04
KR20010014224A (ko) 2001-02-26
CO4950621A1 (es) 2000-09-01
ID24345A (id) 2000-07-13
TR199903257T2 (xx) 2000-12-21
US20030100561A1 (en) 2003-05-29
HRP980361A2 (en) 1999-02-28
HN1998000088A (es) 1999-01-08
HUP0001922A3 (en) 2001-02-28
PE105399A1 (es) 1999-11-04
CN1259140A (zh) 2000-07-05
JP2005097261A (ja) 2005-04-14
YU70199A (sh) 2003-01-31
IL156465A (en) 2004-07-25
IL156465A0 (en) 2004-01-04
AP1145A (en) 2003-02-14
HK1028051A1 (en) 2001-02-02
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
IL154116A0 (en) 2003-07-31
ATE305477T1 (de) 2005-10-15
TNSN98113A1 (fr) 2005-03-15
US6867202B1 (en) 2005-03-15
CN1530107A (zh) 2004-09-22
IL133626A0 (en) 2001-04-30
US6448263B1 (en) 2002-09-10
PL337659A1 (en) 2000-08-28
EA199901075A1 (ru) 2000-08-28
ZA985546B (en) 2000-01-10
JP2000514099A (ja) 2000-10-24
BR9810477A (pt) 2007-05-22
EG21712A (en) 2002-02-27
CA2294464A1 (en) 1998-12-30
JP3742643B2 (ja) 2006-02-08
OA11242A (en) 2003-07-23
UA64751C2 (uk) 2004-03-15
AU747510B2 (en) 2002-05-16
ES2248899T3 (es) 2006-03-16
BG104008A (en) 2000-07-31
DE69831745D1 (de) 2006-02-09
SK175699A3 (en) 2001-04-09
DZ2539A1 (fr) 2003-02-08

Similar Documents

Publication Publication Date Title
NO996205D0 (no) Behandling av insulinresistens med veksthormonutskillelsesmiddel
FI963482A0 (fi) Menetelmä hematopoieesin stimuloimiseksi hemoglobiinilla
NO973446L (no) Forbindelser med veksthormonfrigjörende egenskaper
FI952930A7 (fi) Pysyvien sinkki-insuliinianalogikiteiden valmistaminen
DE69531573D1 (de) Implantierbare rohrförmige Prothese mit Manschetten
DE69837264D1 (de) Dipeptidderivate zur förderung der sekretion von wachstumshormon
DK0885961T3 (da) Hidtil ukendte insulinderivater med hurtig indtræden af virkning
EP0741578A4 (en) HUMAN GROWTH HORMONE
DE69731979D1 (de) Dialysekatheter mit starren und kollabierbaren lumina
NO20001242L (no) April - et nytt protein med veksteffekter
DE69942928D1 (de) Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
EE200100479A (et) Kasvuhormooni nõristitena kasulikud heterotsüklilised aromaatsed ühendid ja nende kasutamine
PL338883A1 (en) Growth hormone secretion stimulating compounds
NO991186L (no) Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
NO975992D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
DE69309698D1 (de) Hautbehandlung mit adhäsionsverstärkenden eigenschaften
PL329851A1 (en) Treatment of diseases associated with vegf
AU9471598A (en) Treatment of congestive heart failure with growth hormone secretagogues
DK0907358T3 (da) Behandling med ensartet afgivelse af lægemiddel
NO996265D0 (no) Behandling av diabetes med rosiglitazon og insulin
PL347659A1 (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
DE69904407D1 (de) Automatische Insulininjektionsspritze mit Arztmode
AU7609298A (en) Treatment of heart failure with growth hormone
SI1007085T1 (en) Use of growth hormone in compositions for treating insulin resistance in the heart
AUPP582198A0 (en) Modified human growth hormone

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application